基于临床实验室的p2PSA指数对任何级别、Gleason分级分组≥2或≥3的前列腺癌及前列腺特异性抗原低于10 ng/ml的诊断影响
PROPHET为前瞻性研究,纳入421名50-79岁PSA高于年龄特异 cutoffs 且低于10 ng/ml的男性,评估基于实验室的游离PSA相关及p2PSA相关指数对任何级别及高Gleason分级分组前列腺癌的诊断价值。在363名合格参与者中,PHI区分前列腺癌与非前列腺癌等的AUC-ROC显著优于PSA和f/tPSA;在90%灵敏度下,所有p2PSA相关指数的假阳性率优于PSA和f/tPSA;PHI可避免35%-42%无前列腺癌和/或侵袭性较低前列腺癌男性的不必要活检。
要点
- 基于实验室的p2PSA相关指数在检测临床显著前列腺癌方面显著优于游离/总PSA比值。
- 在90%灵敏度下,p2PSA相关指数的假阳性率在Gleason分级分组和阳性活检针数方面均优于PSA和f/tPSA。
- PHI可使35%-42%无前列腺癌和/或侵袭性较低前列腺癌的男性避免不必要的活检。
核心结论
- 基于实验室的p2PSA相关指数在检测临床显著前列腺癌方面显著优于游离/总PSA比值。
- 这些指数可在维持90%灵敏度的同时,使高达42%无侵袭性癌症的男性避免前列腺活检。
研究设计与样本
- PROPHET(Prostate Cancer: Prostate Health Index Trial)为前瞻性研究,于2015年4月至2017年3月注册421名50至79岁、PSA高于年龄特异 cutoffs 且低于10 ng/ml的男性。
- 共363名合格参与者纳入分析。
主要发现
- 363名合格参与者中,分别有179、141和80例诊断为任何级别、Gleason分级分组2-5和3-5前列腺癌。
- PHI区分非前列腺癌 vs 前列腺癌、非前列腺癌加低Gleason分级分组和低体积 vs 剩余具有更高Gleason分级分组或更高体积的前列腺癌的AUC-ROC显著优于PSA和游离/总PSA的AUC-ROC。
- 在所有研究的p2PSA相关指数中,在90%灵敏度下,任何Gleason分级分组和阳性活检针数的组间比较中,假阳性率均优于PSA和游离/总PSA。
- 在35%至42%无前列腺癌和/或侵袭性较低前列腺癌的男性中,PHI可避免不必要的活检。
关键数值与推荐
- 363名合格参与者中,179例为任何级别前列腺癌,141例为Gleason分级分组2-5,80例为Gleason分级分组3-5。
- 在90%灵敏度下,所有p2PSA相关指数的假阳性率优于PSA和游离/总PSA。
- PHI可避免35%至42%无前列腺癌和/或侵袭性较低前列腺癌男性的不必要活检。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The PROPHET (Prostate Cancer: Prostate Health Index Trial) is a prospective study to clarify the diagnostic impact of laboratory based and prostate volume adjusted p2PSA ([-2] proenzyme prostate specific antigen) related indexes on prostate cancer and clinically significant prostate cancer with prostate specific antigen less than 10 ng/ml. MATERIALS AND METHODS: Between April 2015 and March 2017, 421 men 50 to 79 years old in the prostate specific antigen range above age specific cutoffs and below 10 ng/ml were registered in the PROPHET. We investigated the diagnostic impacts of various clinical laboratory based free prostate specific antigen related and p2PSA related indexes on any grade and high Gleason grade group prostate cancer. RESULTS: Of the 363 eligible participants 179, 141 and 80 were diagnosed with any grade, and Gleason Grade Group 2-5 and 3-5 prostate cancer, respectively. The AUC-ROCs distinguishing nonprostate cancer vs prostate cancer, nonprostate cancer plus low Gleason Grade Group and low volume vs remaining prostate cancer with a higher Gleason Grade group or a higher volume on the PHI (Prostate Health Index) were significantly superior to the AUC-ROCs of prostate specific antigen and free-to-total prostate specific antigen. At 90% sensitivity in all investigated p2PSA related indexes the false-positive rate was superior to that of prostate specific antigen and free-to-total prostate specific antigen in any group comparison in terms of the Gleason Grade Group and positive biopsy cores. In 35% to 42% of men without prostate cancer and/or those with less aggressive prostate cancer the PHI would avoid unnecessary biopsy. CONCLUSIONS: Laboratory based p2PSA related indexes were significantly superior for detecting clinically significant prostate cancer compared to free-to-total prostate specific antigen. The indexes those would avoid up to 42% of prostate biopsies in men without aggressive cancer while maintaining 90% sensitivity.
引用
- Ito K, Yokomizo A, Tokunaga S, et al. Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml. J Urol. 2019. PMID: 31430244. doi:10.1097/JU.0000000000000495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。